📈 Stocks
Goldman Sachs Identifies Two Biotech IPOs With Over 75% Upside Potential
(just now)
Goldman Sachs analyst Salveen Richter initiates coverage on Latigo Biotherapeutics and Braveheart Bio, citing significant clinical potential and large addressable markets for…